These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15070684)

  • 1. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.
    Takahashi H; Ieiri I; Wilkinson GR; Mayo G; Kashima T; Kimura S; Otsubo K; Echizen H
    Blood; 2004 Apr; 103(8):3055-7. PubMed ID: 15070684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
    Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
    Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
    King BP; Khan TI; Aithal GP; Kamali F; Daly AK
    Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
    Tai G; Farin F; Rieder MJ; Dreisbach AW; Veenstra DL; Verlinde CL; Rettie AE
    Pharmacogenet Genomics; 2005 Jul; 15(7):475-81. PubMed ID: 15970795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
    Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
    Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.
    Lee SJ; Jang YJ; Cha EY; Kim HS; Lee SS; Shin JG
    Br J Clin Pharmacol; 2010 Aug; 70(2):213-21. PubMed ID: 20653674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.
    Veenstra DL; Blough DK; Higashi MK; Farin FM; Srinouanprachan S; Rieder MJ; Rettie AE
    Clin Pharmacol Ther; 2005 May; 77(5):353-64. PubMed ID: 15900281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.
    Mushiroda T; Ohnishi Y; Saito S; Takahashi A; Kikuchi Y; Saito S; Shimomura H; Wanibuchi Y; Suzuki T; Kamatani N; Nakamura Y
    J Hum Genet; 2006; 51(3):249-253. PubMed ID: 16432637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.
    Zhang X; Li L; Ding X; Kaminsky LS
    Drug Metab Dispos; 2011 Aug; 39(8):1433-9. PubMed ID: 21562147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
    Cavallari LH; Vaynshteyn D; Freeman KM; Wang D; Perera MA; Takahashi H; Drozda K; Patel SR; Jeong H
    Pharmacogenet Genomics; 2013 Apr; 23(4):228-31. PubMed ID: 23376925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.
    Lindh JD; Holm L; Andersson ML; Rane A
    Eur J Clin Pharmacol; 2009 Apr; 65(4):365-75. PubMed ID: 19031075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
    Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
    Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacogenetics of the response to warfarin in Chinese.
    Lam MP; Cheung BM
    Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
    Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
    J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
    Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
    Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
    Zhao F; Loke C; Rankin SC; Guo JY; Lee HS; Wu TS; Tan T; Liu TC; Lu WL; Lim YT; Zhang Q; Goh BC; Lee SC
    Clin Pharmacol Ther; 2004 Sep; 76(3):210-9. PubMed ID: 15371982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.